Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor John Lunec

Newcastle AuthorsTitleYearFull text
Erhan Aptullahoglu
Mohammed Howladar
Dr Jonathan Wallis
Dr Helen Marr
Professor Julie Irving
et al.		Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia2025
Emerita Professor Nicola Curtin
Dr Sweta Sharma Saha
Professor John Lunec
A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers2024
Dr Hayden Bell
Dr Helen Blair
Samantha Jepson Gosling
Dr Martin Galler
Dan Astley
et al.		Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2024
Dr Celine Cano
Professor Jane Endicott
Dr Ian Hardcastle
Dr Claire Jennings
Suzanne Kyle
et al.		Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile2024
Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796))2024
Erhan Aptullahoglu
Dr Sirintra Nakjang
Dr Jonathan Wallis
Dr Helen Marr
Dr Scott Marshall
et al.		RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia2024
Dr Elaine Willmore
Suzanne Kyle
Dr Yan Zhao
Huw Thomas
Dr Kenneth Rankin
et al.		Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index2024
Erhan Aptullahoglu
Dr Jonathan Wallis
Dr Helen Marr
Dr Elaine Willmore
Professor John Lunec
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia2023
Bassier Zadran
Daniel Wainwright
Dr Yvonne Bury
Dr Saimir Luli
Rachel Howarth
et al.		Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation2023
Dr Carmela Ciardullo
Dr Jonathan Wallis
Dr Helen Marr
Dr Nicholas Bown
Dr Elaine Willmore
et al.		Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition2023
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al.		Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2023
Professor John Lunec
p53 as a biomarker and potential target in gastrointestinal stromal tumors2022
Victoria Chamberlain
Dr Yvette Drew
Professor John Lunec
Tipping growth inhibition into apoptosis by combining treatment with MDM2 and WIP1 inhibitors in p53WT uterine leiomyosarcoma2022
Dr Corey Chan
Dr Emma Haagensen
Dr Hayeit Tensaout
Dr Kate Rennie
Dr Zakareya Gamie
et al.		Co‑localisation of intra‑nuclear membrane type‑1 matrix metalloproteinase and hypoxia inducible factor‑2α in osteosarcoma and prostate carcinoma cells2021
Dr Praveen Dhondurao Sudhindar
Daniel Wainwright
Dr Santu Saha
Rachel Howarth
Misti McCain
et al.		HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway2021
12345678910111213141516